Obesity drug data could boost companies case for US coverage analysts say Reuters

Aug 10 (Reuters) – New data on the heart benefit of an obesity drug from Novo Nordisk (NOVOb.CO) increases the chances of a pay-off for it and Eli Lilly, which have spent a record amount on U.S. lobb… [+5211 chars]Read More